FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Gabor Halmos

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Tumor Cells, Cultured

Procedures

Physiology

Cell Divisions

Disorders

Prostatic Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Ferenc Rick; Andrew Abi-Chaker; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Arumugam R Jayakumar; AWTAR KRISHAN; Roberto Perez; Nagarajarao Shamaladevi; Luca Szalontay; Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Karoly Szepeshazi; Irving Vidaurre; Norman Block; Gabor Halmos; Ferenc Rick; Andrew V Schally; Luca Szalontay
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally; Luca Szalontay; Daniel Benten; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Gunhild Keller; Ferenc Rick
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Gabor Halmos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Ferenc Rick; Andrew Abi-Chaker; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Arumugam R Jayakumar; AWTAR KRISHAN; Roberto Perez; Nagarajarao Shamaladevi; Luca Szalontay; Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally
Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(7):2617-22.
2012: Karoly Szepeshazi; Irving Vidaurre; Norman Block; Gabor Halmos; Ferenc Rick; Andrew V Schally; Luca Szalontay
Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
Anti-cancer drugs 2012;23(9):906-13.
2012: Karoly Szepeshazi; Irving Vidaurre; Andrew V Schally; Luca Szalontay; Daniel Benten; Norman Block; Gabor Halmos; Miklos Jaszberenyi; Gunhild Keller; Ferenc Rick
Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Oncotarget 2012;3(7):686-99.
2012: Anton Stangelberger; Jozsef Varga; Marta Zarandi; Benjamin Baker; Ferenc Rick; Andrew V Schally; Gabor Halmos
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
The Prostate 2012;72(5):555-65.
2012: Anna Klukovits; Andrea Papadia; Andrew V Schally; Luca Szalontay; Jozsef Varga; Irving Vidaurre; Marta Zarandi; Norman Block; Gabor Halmos
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Cancer 2012;118(3):670-80.
2011: Andrea Papadia; Ferenc Rick; Andrew V Schally; S Seitz; Luca Szalontay; A Treszl; Jozsef Varga; Marta Zarandi; S Bellyei; Stefan Buchholz; Gabor Halmos; Joseph Lucci
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(11):816-20.
2011: Ferenc Rick; Andrew V Schally; Irving Vidaurre; Norman Block; Jesus B Fernandez; Gabor Halmos; Roberto Perez; Luca Szalontay
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
The Prostate 2011;71(7):736-47.
2011: Bernadett Rozsa; Mehrdad Nadji; Andrew V Schally; Balazs Dezso; Tibor Flasko; Gyorgy Toth; Melinda Mile; Norman Block; Gabor Halmos
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
The Prostate 2011;71(5):445-52.
2011: Ferenc Rick; Andrew V Schally; Norman Block; Mehrdad Nadji; Karoly Szepeshazi; Marta Zarandi; Irving Vidaurre; Roberto Perez; Gabor Halmos; Luca Szalontay
Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(9):3755-60.
2010: E Pozsgai; Andrew V Schally; Gabor Halmos; Ferenc Rick; S Bellyei
The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2010;42(11):781-6.
2010: Florian Hohla; Stefan Buchholz; Andrew V Schally; AWTAR KRISHAN; Ferenc Rick; Luca Szalontay; Andrea Papadia; Gabor Halmos; Frank Koster; Elmar Aigner; Christian Datz; Stephan Seitz
Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells.
Cancer letters 2010;294(1):35-42.
2009: Bernadett Rózsa; Aliz Juhász; Andrea Treszl; György Tóth; Tibor Flaskó; Balázs Dezsö; Norman Block; Andrew V Schally; Gabor Halmos
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
International journal of oncology 2009;35(5):1053-9.
2009: Florian Hohla; Stefan Buchholz; Andrew V Schally; Stefan Seitz; Ferenc Rick; Luca Szalontay; Jozsef Varga; Marta Zarandi; Gabor Halmos; Irving Vidaurre; AWTAR KRISHAN; Metin Kurtoglu; Sudhir Chandna; Elmar Aigner; Christian Datz
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2009;8(19):3149-56.
2009: Andrea Treszl; Andrew V Schally; Stephan Seitz; Luca Szalontay; Ferenc Rick; Karoly Szepeshazi; Gabor Halmos
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Peptides 2009;30(9):1643-50.
2009: Stephan Seitz; Andrew V Schally; Andrea Treszl; Andrea Papadia; Ferenc Rick; Luca Szalontay; Karoly Szepeshazi; Olaf Ortmann; Gabor Halmos; Florian Hohla; Stefan Buchholz
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-cancer drugs 2009;20(7):553-8.
2008: Elmar Heinrich; Andrew V Schally; Stefan Buchholz; Ferenc Rick; Gabor Halmos; Melinda Mile; Kate Groot; Florian Hohla; Marta Zarandi; Jozsef Varga
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
The Prostate 2008;68(16):1763-72.
2008: Karoly Szepeshazi; Andrew V Schally; Andrea Treszl; Stephan Seitz; Gabor Halmos
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Anti-cancer drugs 2008;19(4):349-58.
2007: Florian Hohla; Andrew V Schally; Celia A Kanashiro; Stefan Buchholz; Ben Baker; Chandrika Kannadka; Angelika Moder; Elmar Aigner; Christian Datz; Gabor Halmos
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(47):18671-6.
2007: Anton Stangelberger; Andrew V Schally; Marta Zarandi; Elmar Heinrich; Kate Groot; Alexandre Havt; Celia A Kanashiro; Jozsef Varga; Gabor Halmos
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
The Prostate 2007;67(12):1339-53.
2007: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
International journal of oncology 2007;30(6):1485-92.
2007: Stefan Buchholz; Andrew V Schally; Jörg Engel; Florian Hohla; Elmar Heinrich; Frank Koester; Jozsef Varga; Gabor Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(6):1943-6.
2006: Florian Hohla; Andrew V Schally; Karoly Szepeshazi; Jozsef Varga; Stefan Buchholz; Frank Köster; Elmar Heinrich; Gabor Halmos; Ferenc Rick; Chandrika Kannadka; Christian Datz; Celia A Kanashiro
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14513-8.
2006: Stefan Buchholz; Gunhild Keller; Andrew V Schally; Gabor Halmos; Florian Hohla; Elmar Heinrich; Frank Koester; Ben Baker; Jörg Engel
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10403-7.
2006: Gunhild Keller; Andrew V Schally; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
International journal of oncology 2006;28(6):1507-13.
2006: Marta Zarandi; Jozsef Varga; Andrew V Schally; Judit E Horvath; Gabor L Toller; Magdolna Kovacs; Markus Letsch; Kate Groot; Patricia Armatis; Gabor Halmos
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4610-5.
2006: Anton Stangelberger; Andrew V Schally; Attila Nagy; Karoly Szepeshazi; Celia A Kanashiro; Gabor Halmos
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
The Prostate 2006;66(2):200-10.
2006: Anton Stangelberger; Andrew V Schally; Markus Letsch; Karoly Szepeshazi; Attila Nagy; Gabor Halmos; Celia A Kanashiro; Eva Corey; Robert L Vessella
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
International journal of cancer. Journal international du cancer 2006;118(1):222-9.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocrine-related cancer 2005;12(4):999-1009.
2005: Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(48):17424-9.
2005: Gunhild Keller; Andrew V Schally; Attila Nagy; Gabor Halmos; Ben Baker; Jörg Engel
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer 2005;104(10):2266-74.
2005: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Gabor Halmos
Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas 2005;31(3):275-82.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer 2005;104(6):1312-21.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2196-202.
2005: Celia A Kanashiro; Andrew V Schally; Jozsef Varga; Brian D Hammann; Gabor Halmos; Marta Zarandi
Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Cancer letters 2005;226(2):123-31.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabor Halmos; Jörg Engel
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5549-57.
2005: Jörg Engel; Andrew V Schally; Gabor Halmos; Ben Baker; Attila Nagy; Gunhild Keller
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1824-30.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Brian D Hammann; Kate Groot; Gabor Halmos; Renzhi Cai; Marta Zarandi
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
The Prostate 2005;64(3):303-15.
2005: Gunhild Keller; Andrew V Schally; Kate Groot; Gabor L Toller; Alexandre Havt; Frank Köster; Patricia Armatis; Gabor Halmos; Marta Zarandi; Jozsef Varga; Jörg Engel
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10628-33.
2005: Gunhild Keller; Andrew V Schally; Timo Gaiser; Attila Nagy; Ben Baker; Gabriela Westphal; Gabor Halmos; Jörg Engel
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer research 2005;65(13):5857-63.
2005: Celia A Kanashiro; Andrew V Schally; Attila Nagy; Gabor Halmos
Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
International journal of oncology 2005;27(1):169-74.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Gabor L Toller; Kate Groot; Alexandre Havt; Patricia Armatis; Marta Zarandi; Jozsef Varga; Gabor Halmos
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
The Journal of clinical endocrinology and metabolism 2005;90(6):3614-21.
2005: Gunhild Keller; Jörg Engel; Andrew V Schally; Attila Nagy; Brian D Hammann; Gabor Halmos
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
International journal of cancer. Journal international du cancer 2005;114(5):831-5.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Attila Nagy; David D Chism; Gabor Halmos
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertility and sterility 2005;83 Suppl 1():1125-33.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Gabor Halmos; Brian D Hammann; Attila Nagy
Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2408-15.
2005: Celia A Kanashiro; Andrew V Schally; Renzhi Cai; Gabor Halmos
Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Anti-cancer drugs 2005;16(2):159-65.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Marta Zarandi; Karoly Szepeshazi; Patricia Armatis; Gabor Halmos
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):49-57.
2004: Gabor L Toller; Judit E Horvath; Andrew V Schally; Gabor Halmos; Jozsef Varga; Kate Groot; David Chism; Marta Zarandi
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(42):15160-5.
2004: Andrew V Schally; Karoly Szepeshazi; Attila Nagy; Ana Maria Comaru-Schally; Gabor Halmos
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cellular and molecular life sciences : CMLS 2004;61(9):1042-68.
2004: Jozsef Varga; Andrew V Schally; Judit E Horvath; Magdolna Kovacs; Gabor Halmos; Kate Groot; Gabor L Toller; Zoltan Rekasi; Marta Zarandi
Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(6):1708-13.
2004: Markus Letsch; Andrew V Schally; Karoly Szepeshazi; Gabor Halmos; Attilla Nagy
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
The Journal of urology 2004;171(2 Pt 1):911-5.
2003: Zoltan Szereday; Andrew V Schally; Jozsef Varga; Celia A Kanashiro; Francine Hebert; Patricia Armatis; Kate Groot; Karoly Szepeshazi; Gabor Halmos; Rebeca Busto
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer research 2003;63(22):7913-9.
2003: Markus Letsch; Andrew V Schally; Karoly Szepeshazi; Gabor Halmos; Attila Nagy
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4505-13.
2003: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Brady W Wagner; Ana M Bajo; Gabor Halmos
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer 2003;98(7):1401-10.
2003: Ana M Bajo; Andrew V Schally; Gabor Halmos; Attila Nagy
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3742-8.
2003: Hippokratis Kiaris; Ioulia Chatzistamou; Andrew V Schally; Gabor Halmos; Jozsef Varga; Helen Koutselini; Anastasios Kalofoutis
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(16):9512-7.
2003: Zoltan Szereday; Andrew V Schally; Karoly Szepeshazi; Ana M Bajo; Francine Hebert; Gabor Halmos; Attila Nagy
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
International journal of oncology 2003;22(5):1141-6.
2003: Gabor Halmos; Andrew V Schally; Ana Maria Comaru-Schally; Attila Nagy; Anand Irimpen
Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
Life sciences 2003;72(23):2669-74.
2002: Gabor Halmos; Andrew V Schally; Tamas Czompoly; Magdalena Krupa; Jozsef Varga; Zoltan Rekasi
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
The Journal of clinical endocrinology and metabolism 2002;87(10):4707-14.
2002: Artur Plonowski; Andrew V Schally; Rebeca Busto; Magdalena Krupa; Jozsef Varga; Gabor Halmos
Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Peptides 2002;23(6):1127-33.
2002: Zoltan Szereday; Andrew V Schally; Attila Nagy; Artur Plonowski; Ana M Bajo; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
British journal of cancer 2002;86(8):1322-7.
2002: Artur Plonowski; Jozsef Varga; Andrew V Schally; Magdalena Krupa; Kate Groot; Gabor Halmos
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
International journal of cancer. Journal international du cancer 2002;98(4):624-9.
2002: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Patricia Armatis; Francine Hebert; Baodong Sun; Anita Feil; Hippokratis Kiaris; Attila Nagy
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research 2002;62(3):781-8.
2002: Artur Plonowski; Andrew V Schally; Attila Nagy; Baodong Sun; Gabor Halmos
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
International journal of oncology 2002;20(2):397-402.
2002: Gabor Halmos; Andrew V Schally
Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(2):961-5.
2001: Ioulia Chatzistamou; Andrew V Schally; Jozsef Varga; Kate Groot; Rebeca Busto; Patricia Armatis; Gabor Halmos
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.
Anti-cancer drugs 2001;12(9):761-8.
2001: Andrew V Schally; Ana Maria Comaru-Schally; Attila Nagy; Magdolna Kovacs; Karoly Szepeshazi; Artur Plonowski; Jozsef Varga; Gabor Halmos
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Karoly Szepeshazi; Andrew V Schally; Patricia Armatis; Kate Groot; Francine Hebert; A Feil; Jozsef Varga; Gabor Halmos
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology 2001;142(10):4371-8.
2001: Artur Plonowski; Andrew V Schally; Miklos Koppan; Attila Nagy; Jose M Arencibia; Balazs Csernus; Gabor Halmos
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Cancer 2001;92(5):1168-76.
2001: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Baodong Sun; Francine Hebert; Balazs Csernus; Attila Nagy
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2854-61.
2001: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Artur Plonowski; Gabor Halmos; Balazs Csernus; Patricia Armatis; Kate Groot
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides 2001;22(6):879-86.
2001: Ioulia Chatzistamou; Andrew V Schally; Jozsef Varga; Kate Groot; Patricia Armatis; Rebeca Busto; Gabor Halmos
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
The Journal of clinical endocrinology and metabolism 2001;86(5):2144-52.
2001: Hippokratis Kiaris; Andrew V Schally; Attila Nagy; Karoly Szepeshazi; Francine Hebert; Gabor Halmos
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
European journal of cancer (Oxford, England : 1990) 2001;37(5):620-8.
2001: Jose M Arencibia; Andrew V Schally; Gabor Halmos; Attila Nagy; Hippokratis Kiaris
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Anti-cancer drugs 2001;12(1):71-8.
2000: Artur Plonowski; Attila Nagy; Andrew V Schally; Baodong Sun; Kate Groot; Gabor Halmos
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
International journal of cancer. Journal international du cancer 2000;88(4):652-7.
2000: Gabor Halmos; Baodong Sun; Andrew V Schally; Francine Hebert; Attila Nagy
Human ovarian cancers express somatostatin receptors.
The Journal of clinical endocrinology and metabolism 2000;85(10):3509-12.
2000: L Chatzistamou; Andrew V Schally; Attila Nagy; Patricia Armatis; Karoly Szepeshazi; Gabor Halmos
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4158-65.
2000: Andrew V Schally; Ana Maria Comaru-Schally; Artur Plonowski; Attila Nagy; Gabor Halmos; Zoltan Rekasi
Peptide analogs in the therapy of prostate cancer.
The Prostate 2000;45(2):158-66.
2000: Zoltan Rekasi; Tamas Czompoly; Andrew V Schally; Gabor Halmos
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10561-6.
2000: Gabor Halmos; Andrew V Schally; Jozsef Varga; Artur Plonowski; Zoltan Rekasi; Tamas Czompoly
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10555-60.
2000: Gabor Halmos; Andrew V Schally; Z Kahan
Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
International journal of oncology 2000;17(2):367-73.
2000: Gabor Halmos; Andrew V Schally; Baodong Sun; R Davis; D G Bostwick; Artur Plonowski
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
The Journal of clinical endocrinology and metabolism 2000;85(7):2564-71.
2000: Artur Plonowski; Andrew V Schally; Jozsef Varga; Zoltan Rekasi; Francine Hebert; Gabor Halmos; Kate Groot
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
The Prostate 2000;44(2):172-80.
2000: B Sun; Andrew V Schally; Gabor Halmos
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.
Regulatory peptides 2000;90(1-3):77-84.
2000: Artur Plonowski; Andrew V Schally; Attila Nagy; Hippokratis Kiaris; Francine Hebert; Gabor Halmos
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Cancer research 2000;60(11):2996-3001.
2000: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Gabor Halmos; Patricia Armatis; Kate Groot; Tamas Czompoly
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Endocrinology 2000;141(6):2120-8.
2000: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Patricia Armatis; Gabor Halmos; F Herbert; Béla Szende; Jozsef Varga; Marta Zarandi
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
British journal of cancer 2000;82(10):1724-31.
2000: Z Kahán; Baodong Sun; Andrew V Schally; Jose M Arencibia; Renzhi Cai; Kate Groot; Gabor Halmos
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Cancer 2000;88(6):1384-92.
2000: Z Kahán; Jozsef Varga; Andrew V Schally; Z Rékási; Patricia Armatis; L Chatzistamou; T Czömpöly; Gabor Halmos
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Breast cancer research and treatment 2000;60(1):71-9.
2000: Baodong Sun; Gabor Halmos; Andrew V Schally; X Wang; M Martinez
Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
The Prostate 2000;42(4):295-303.
2000: Z Kahán; Attila Nagy; Andrew V Schally; Gabor Halmos; Jose M Arencibia; Kate Groot
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Breast cancer research and treatment 2000;59(3):255-62.
2000: Hippokratis Kiaris; Andrew V Schally; Attila Nagy; Baodong Sun; Karoly Szepeshazi; Gabor Halmos
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):709-17.
2000: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Gabor Halmos; Kate Groot; Tamas Czompoly
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1218-23.
2000: Gabor Halmos; Jose M Arencibia; Andrew V Schally; R Davis; D G Bostwick
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
The Journal of urology 2000;163(2):623-9.
2000: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Patricia Armatis; Francine Hebert; Gabor Halmos
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(1):128-36.
1999: Z Kahán; Attila Nagy; Andrew V Schally; Francine Hebert; Baodong Sun; Kate Groot; Gabor Halmos
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
International journal of cancer. Journal international du cancer 1999;82(4):592-8.
1999: K Szepesházi; Gabor Halmos; Andrew V Schally; Jose M Arencibia; Kate Groot; M Vadillo-Buenfil; E Rodriguez-Martin
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Journal of cancer research and clinical oncology 1999;125(8-9):444-52.
1999: Z Kahán; Attila Nagy; Andrew V Schally; Gabor Halmos; Jose M Arencibia; Kate Groot
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Cancer 1999;85(12):2608-15.
1999: M Miyazaki; Andrew V Schally; Attila Nagy; N Lamharzi; Gabor Halmos; Karoly Szepeshazi; Patricia Armatis
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
American journal of obstetrics and gynecology 1999;180(5):1095-103.
1999: Gabor Halmos; Attila Nagy; N Lamharzi; Andrew V Schally
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Cancer letters 1999;136(2):129-36.
1999: M Koppán; Attila Nagy; Andrew V Schally; Artur Plonowski; Gabor Halmos; Jose M Arencibia; Kate Groot
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
The Prostate 1999;38(2):151-8.
1999: Jozsef Varga; Andrew V Schally; VJ Csernus; Márta Zarándi; Gabor Halmos; Kate Groot; Z Rékási
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):692-7.
1998: M Koppán; Gabor Halmos; Jose M Arencibia; N Lamharzi; Andrew V Schally
Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Cancer 1998;83(7):1335-43.
1998: Miklos Koppan; Attila Nagy; Andrew V Schally; Jose M Arencibia; Artur Plonowski; Gabor Halmos
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Cancer research 1998;58(18):4132-7.
1998: N Lamharzi; Gabor Halmos; Andreas Jungwirth; Andrew V Schally
Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
International journal of oncology 1998;13(3):429-35.
1998: M Miyazaki; N Lamharzi; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Renzhi Cai
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
European journal of cancer (Oxford, England : 1990) 1998;34(5):710-7.
1998: Andreas Jungwirth; Andrew V Schally; Gabor Halmos; Kate Groot; Karoly Szepeshazi; Jacek Pinski; Patricia Armatis
Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Cancer 1998;82(5):909-17.
1998: N Lamharzi; Gabor Halmos; Patricia Armatis; Andrew V Schally
Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.
International journal of oncology 1998;12(3):671-5.
1998: Attila Nagy; Andrew V Schally; Gabor Halmos; Patricia Armatis; Renzhi Cai; VJ Csernus; M Kovács; M Koppán; K Szepesházi; Z Kahán
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1794-9.
1998: K Toth; Magdolna Kovacs; Marta Zarandi; Gabor Halmos; Kate Groot; Attila Nagy; Z Kele; Andrew V Schally
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
The journal of peptide research : official journal of the American Peptide Society 1998;51(2):134-41.
1997: M Miyazaki; Attila Nagy; Andrew V Schally; N Lamharzi; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Patricia Armatis
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute 1997;89(23):1803-9.
1997: Karoly Szepeshazi; Andrew V Schally; Attila Nagy; Gabor Halmos; Kate Groot
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anti-cancer drugs 1997;8(10):974-87.
1997: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; N Lamharzi; Kate Groot; Judit E Horvath
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(20):10913-8.
1997: Andreas Jungwirth; G Galvan; Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Renzhi Cai; Kate Groot; Andrew V Schally
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
The Prostate 1997;32(3):164-72.
1997: Andreas Jungwirth; Jacek Pinski; G Galvan; Gabor Halmos; Karoly Szepeshazi; Renzhi Cai; Kate Groot; M Vadillo-Buenfil; Andrew V Schally
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1141-8.
1997: Andreas Jungwirth; Andrew V Schally; Jacek Pinski; Kate Groot; Patricia Armatis; Gabor Halmos
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(11):5810-3.
1997: Gabor Halmos; Andrew V Schally
Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(3):956-60.
1997: Attila Nagy; Patricia Armatis; Renzhi Cai; Karoly Szepeshazi; Gabor Halmos; Andrew V Schally
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(2):652-6.
1997: Andreas Jungwirth; Andrew V Schally; Jacek Pinski; Gabor Halmos; Kate Groot; Patricia Armatis; M Vadillo-Buenfil
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
British journal of cancer 1997;75(11):1585-92.
1997: Marta Zarandi; Magdolna Kovacs; Judit E Horvath; K Toth; Gabor Halmos; Kate Groot; Attila Nagy; Z Kele; Andrew V Schally
Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides 1997;18(3):423-30.
1996: Magdolna Kovacs; Márta Zarándi; Gabor Halmos; Kate Groot; Andrew V Schally
Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Endocrinology 1996;137(12):5364-9.
1996: M Kovács; Gabor Halmos; Kate Groot; J Izdebski; Andrew V Schally
Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.
Neuroendocrinology 1996;64(3):169-76.
1996: Jacek Pinski; N Lamharzi; Gabor Halmos; Kate Groot; Andreas Jungwirth; M Vadillo-Buenfil; S S Kakar; Andrew V Schally
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Endocrinology 1996;137(8):3430-6.
1996: Attila Nagy; Andrew V Schally; Patricia Armatis; Karoly Szepeshazi; Gabor Halmos; Magdolna Kovacs; Marta Zarandi; Kate Groot; M Miyazaki; Andreas Jungwirth; J Horvath
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7269-73.
1996: Gabor Halmos; Andrew V Schally; Jacek Pinski; M Vadillo-Buenfil; Kate Groot
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2398-402.
1996: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice.
International journal of cancer. Journal international du cancer 1996;65(6):870-4.
1996: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; B Szoke; Kate Groot; Attila Nagy
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast cancer research and treatment 1996;40(2):129-39.
1995: Jacek Pinski; Andrew V Schally; Kate Groot; Gabor Halmos; Karoly Szepeshazi; Marta Zarandi; Patricia Armatis
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
Journal of the National Cancer Institute 1995;87(23):1787-94.
1995: J Izdebski; Jacek Pinski; Judit E Horvath; Gabor Halmos; Kate Groot; Andrew V Schally
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(11):4872-6.
1995: Gabor Halmos; J L Wittliff; Andrew V Schally
Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
Cancer research 1995;55(2):280-7.
1994: Marta Zarandi; Judit E Horvath; Gabor Halmos; Jacek Pinski; Attila Nagy; Kate Groot; Z Rekasi; Andrew V Schally
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12298-302.
1994: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Cancer research 1994;54(22):5895-901.
1994: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi; Kate Groot; K O'Byrne; Renzhi Cai
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
British journal of cancer 1994;70(5):886-92.
1994: Jacek Pinski; H Reile; Gabor Halmos; Kate Groot; Andrew V Schally
Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
International journal of cancer. Journal international du cancer 1994;59(1):51-5.
1994: K Szepshazi; Gabor Halmos; Kate Groot; Andrew V Schally
Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
International journal of pancreatology : official journal of the International Association of Pancreatology 1994;16(2-3):141-9.
1994: Gabor Halmos; Jacek Pinski; B Szoke; Andrew V Schally
Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.
Cancer letters 1994;85(1):111-8.
1994: T Yano; Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Kate Groot; Andrew V Schally
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(15):7090-4.
1994: Jacek Pinski; Gabor Halmos; T Yano; Karoly Szepeshazi; Y Qin; T Ertl; Andrew V Schally
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
International journal of cancer. Journal international du cancer 1994;57(4):574-80.
1994: Y Qin; T Ertl; Renzhi Cai; Gabor Halmos; Andrew V Schally
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Cancer research 1994;54(4):1035-41.
1994: T Yano; Jacek Pinski; Karoly Szepeshazi; Gabor Halmos; S Radulovic; K Groot; Andrew V Schally
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Cancer 1994;73(4):1229-38.
1994: Y Qin; Gabor Halmos; Renzhi Cai; B Szoke; T Ertl; Andrew V Schally
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
Journal of cancer research and clinical oncology 1994;120(9):519-28.
1994: B Szöke; J Horváth; Gabor Halmos; Z Rékási; Kate Groot; Attila Nagy; Andrew V Schally
LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
Peptides 1994;15(2):359-66.
1994: Sinisa Radulovic; Andrew V Schally; H Reile; Gabor Halmos; Karoly Szepeshazi; Kate Groot; S Milovanovic; G Miller; T Yano
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
Acta oncologica (Stockholm, Sweden) 1994;33(6):693-701.
1994: Jacek Pinski; H Reile; Gabor Halmos; Kate Groot; Andrew V Schally
Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Cancer research 1994;54(1):169-74.
1994: Béla Szende; A Csikós; Karoly Szepeshazi; Jimmy Neill; J J Mulchahey; Gabor Halmos; Károly Lapis; Andrew V Schally
The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
Receptor 1994;4(4):201-7.
1994: Y Shirahige; Renzhi Cai; Karoly Szepeshazi; Gabor Halmos; Jacek Pinski; Kate Groot; Andrew V Schally
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1994;48(10):465-72.
1994: K J O'Byrne; Gabor Halmos; Jacek Pinski; Kate Groot; Karoly Szepeshazi; Andrew V Schally; D N Carney
Somatostatin receptor expression in lung cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1682-7.
1993: Jacek Pinski; Andrew V Schally; Gabor Halmos; Karoly Szepeshazi
Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
International journal of cancer. Journal international du cancer 1993;55(6):963-7.
1993: Jacek Pinski; Gabor Halmos; Karoly Szepeshazi; Andrew V Schally
Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Cancer 1993;72(11):3263-70.
1993: Jacek Pinski; Gabor Halmos; Y Shirahige; J L Wittliff; Andrew V Schally
Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.
The Journal of clinical endocrinology and metabolism 1993;77(5):1388-92.
1993: Jacek Pinski; Gabor Halmos; Andrew V Schally
Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Cancer letters 1993;71(1-3):189-96.
1993: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Gabor Halmos
Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
International journal of cancer. Journal international du cancer 1993;54(2):282-9.
1993: Jacek Pinski; Andrew V Schally; T Yano; Karoly Szepeshazi; Gabor Halmos; Kate Groot; A M Comaru-Schally; Sinisa Radulovic; Attila Nagy
Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
The Prostate 1993;23(2):165-78.
1993: Gabor Halmos; Z Rekasi; B Szoke; Andrew V Schally
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone.
Receptor 1993;3(2):87-97.
1992: Karoly Szepeshazi; Andrew V Schally; Gabor Halmos; Kate Groot; Sinisa Radulovic
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Journal of the National Cancer Institute 1992;84(24):1915-22.
1992: Tamás Janáky; A Juhász; Z Rékási; P Serfözö; Jacek Pinski; L Bokser; G Srkalovic; S Milovanovic; T W Redding; Gabor Halmos
Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10203-7.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.